Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BraimTOR-NEURO rapamycin study in pediatric drug-resistant epilepsy
2021-006702-78Phase 2Active
- Sponsor
- Children's Memorial Health Institute
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in epilepsy, cortical dysplasia (FCD), dysembryoplastic neuroepithelial tumor (DNET) and 1 more (2 arms), sponsored by Children's Memorial Health Institute. Primary endpoint: Incidence of adverse reactions. Started Apr 2022; status: active.
02
Drugs
sirolimus
03
Conditions
epilepsycortical dysplasia (FCD)dysembryoplastic neuroepithelial tumor (DNET)central nervous system conditions (CNSD)
Beyond the preview
Go deeper on 2021-006702-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006702-78.